Jin Wenwen, Jiang Wei
Department of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Human Genetics Resource Preservation Center of Wuhan University, Wuhan, 430071, China.
Cell Regen. 2022 Aug 1;11(1):24. doi: 10.1186/s13619-022-00125-8.
Pancreatic β cells differentiated from stem cells provide promise for cell replacement therapy of diabetes. Human pluripotent stem cells could be differentiated into definitive endoderm, followed by pancreatic progenitors, and then subjected to endocrinal differentiation and maturation in a stepwise fashion. Many achievements have been made in making pancreatic β cells from human pluripotent stem cells in last two decades, and a couple of phase I/II clinical trials have just been initiated. Here, we overview the major progresses in differentiating pancreatic β cells from human pluripotent stem cells with the focus on recent technical advances in each differentiation stage, and briefly discuss the current limitations as well.
从干细胞分化而来的胰腺β细胞为糖尿病的细胞替代疗法带来了希望。人类多能干细胞可分化为确定的内胚层，随后分化为胰腺祖细胞，然后逐步进行内分泌分化和成熟。在过去二十年中，利用人类多能干细胞生成胰腺β细胞已取得了许多成果，并且刚刚启动了几项I/II期临床试验。在此，我们概述了从人类多能干细胞分化胰腺β细胞的主要进展，重点关注每个分化阶段的最新技术进展，并简要讨论当前的局限性。
